In Brief: Protein Polymer Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Protein Polymer Technologies, Inc.: Development stage biomaterials firm is seeking new partners for development and commercialization of tissue adhesive/sealant technology for use in wound closure following the decision by Johnson & Johnson's Ethicon division to terminate effective Dec. 17 its contract with PPTI covering R&D and commercialization of its protein polymer-based technology...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.